PFIZER INC (PFE)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for PFE
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PFE | Chairman and CEO | 64 | ["30 years of leadership experience","Expertise in medicine and science","Experience in global healthcare and regulatory environment","Former COO of Pfizer","President and General Manager of Established Products Business Unit of Pfizer"] | ["Board of Pharmaceutical Research and Manufacturers of America (PhRMA)","The Pfizer Foundation","Partnership for New York City","Catalyst"] | 2026 |
Biography sourced from the proxy statement filing.
Albert Bourla, DVM, Ph.D., serves as the Chairman and CEO of Pfizer Inc., a leading global pharmaceutical company. Born in Thessaloniki, Greece, Bourla earned his Doctor of Veterinary Medicine from Aristotle University and later obtained a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Thessaloniki. He joined Pfizer in 1993 and has held various leadership positions within the company, including President and General Manager of Pfizer's Established Products Business Unit in Europe, and Group President of Pfizer's Global Vaccines, Oncology, and Consumer Healthcare business.
In his current role as Chairman and CEO, Bourla has been instrumental in guiding Pfizer through significant milestones, such as the development and distribution of the COVID-19 vaccine in collaboration with BioNTech. Under his leadership, Pfizer has continued to focus on innovation, investing heavily in research and development to bring new treatments and therapies to patients worldwide. Bourla's strategic vision has helped Pfizer maintain its position as a leader in the pharmaceutical industry, with a strong emphasis on science, technology, and global health.
Outside of his role at Pfizer, Bourla serves on several boards and organizations. He is a member of the Board of Pharmaceutical Research and Manufacturers of America (PhRMA), The Pfizer Foundation, Partnership for New York City, and Catalyst. These affiliations reflect his commitment to advancing the pharmaceutical industry, supporting scientific research, and fostering economic growth. Bourla is not an independent board member at Pfizer, as he holds the position of Chairman and CEO. His expertise spans various areas, including Business Leadership & Operations, Healthcare & Pharma, International Business, Medicine & Science, and Human Capital Management, making him a valuable asset to the company and the broader industry.
In 2018, Bourla was appointed as the CEO of Pfizer, succeeding Ian Read. Since taking on this role, he has worked tirelessly to drive the company's growth and success, navigating challenges such as the global pandemic and the evolving healthcare landscape. Bourla's leadership has been recognized by various organizations, and he has been named one of the world's most influential people by Time magazine. With his strong background in science, business, and management, Albert Bourla continues to play a crucial role in shaping the future of Pfizer and the pharmaceutical industry as a whole.